We assessed SSEPs, a common clinical index of cortical excitability, as a candidate biomarker to optimize the programming of cerebellar neuromodulation devices for stroke recovery. Collected as part of a phase I clinical trial of deep brain stimulation for stroke, this work provides first in-human evidence that cerebellar stimulation acutely modulates both early and late stages of cortical sensory processing. We show that SSEPs, therefore, may be of future use for the programming of cerebellar neuromodulation devices.
No takes yet. Share an insight, caveat, or question.
Slobodin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: